Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | REN | P00797 | 5/20 | 0.40 |
| ▸ | OPRD1 | P41143 | 6/20 | 0.38 |
| ▸ | CCKAR | P32238 | 5/20 | 0.38 |
| ▸ | CCKBR | P32239 | 5/20 | 0.38 |
| ▸ | BACE1 | P56817 | 3/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30438040 | 0.94 | GLP1R (0.38) | RENOPRD1 | |
| SCHEMBL30437059 | 0.92 | REN (0.39) | RENOPRD1CCKARCCKBRBACE1 | |
| SCHEMBL34461945 | 0.89 | REN (0.40) | RENOPRD1CCKARCCKBRBACE1 | |
| SCHEMBL31088668 | 0.89 | REN (0.36) | RENOPRD1CCKARCCKBR | |
| SCHEMBL30836804 | 0.88 | REN (0.42) | RENOPRD1CCKARCCKBR | |
| SCHEMBL30096878 | 0.88 | REN (0.37) | RENOPRD1CCKARCCKBR | |
| SCHEMBL34461946 | 0.87 | REN (0.39) | RENOPRD1CCKARCCKBR | |
| SCHEMBL29555524 | 0.87 | OPRD1 (0.41) | RENOPRD1CCKARCCKBR | |
| SCHEMBL30437554 | 0.86 | PSEN1 (0.37) | RENOPRD1 | |
| SCHEMBL29554598 | 0.86 | REN (0.37) | RENOPRD1CCKARCCKBR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230220036-A1 | IMPROVED PROCESS FOR THE PREPARATION OF SEMAGLUTIDE | NEULAND LABORATORIES LTD (IN) | 2023-07-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230220036-A1 | IMPROVED PROCESS FOR THE PREPARATION OF SEMAGLUTIDE | GCG, OGDH, ABAT | REN 1559/4885OPRD1 1080/4885CCKAR 479/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.